drugset / Trial / NCT01986348
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
RandomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
Timeline
- Start
- 2014-03-03
- Primary completion
- 2020-01-23
- Completion
- 2020-01-23
Outcome
Outcome not reported
Stopped (Business): “Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 50 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |